• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

直接肾素抑制与 AT1R 阻断对转基因 Ren2 大鼠肾小球滤过屏障损伤的比较作用。

Comparative effect of direct renin inhibition and AT1R blockade on glomerular filtration barrier injury in the transgenic Ren2 rat.

机构信息

Department of Internal Medicine, University of Missouri-Columbia School of Medicine, Columbia, Missouri 65212, USA.

出版信息

Am J Physiol Renal Physiol. 2010 Mar;298(3):F655-61. doi: 10.1152/ajprenal.00373.2009. Epub 2009 Dec 9.

DOI:10.1152/ajprenal.00373.2009
PMID:20007350
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC2838585/
Abstract

Renin-angiotensin system (RAS) activation contributes to kidney injury through oxidative stress. Renin is the rate-limiting step in angiotensin (ANG II) generation. Recent work suggests renin inhibition improves proteinuria comparable to ANG type 1 receptor (AT1R) blockade (ARB). Thereby, we investigated the relative impact of treatment with a renin inhibitor vs. an ARB on renal oxidative stress and associated glomerular structural and functional changes in the transgenic Ren2 rat, which manifests hypertension, albuminuria, and increased tissue RAS activity. Young Ren2 and age-matched Sprague-Dawley (SD) controls (age 6-9 wk) were treated with a renin inhibitor (aliskiren), an ARB (irbesartan), or vehicle for 21 days. Ren2 rats exhibited increases in systolic pressure (SBP), albuminuria, and renal 3-nitrotyrosine content as well as ultrastructural podocyte foot-process effacement and diminution of the podocyte-specific protein nephrin. Structural and functional alterations were accompanied by increased renal cortical ANG II, AT1R, as well as NADPH oxidase subunit (Nox2) expression compared with SD controls. Abnormalities were attenuated to a similar extent with both aliskiren and irbesartan treatment. Despite the fact the dose of irbesartan used caused a greater reduction in SBP than aliskerin treatment (P < 0.05), the effects on proteinuria, nephrin, and oxidative stress were similar between the two treatments. Our results highlight both the importance of pressor-related reductions on podocyte integrity and albuminuria as well as RAS-mediated oxidant stress largely comparable between ARB and renin inhibition treatment.

摘要

肾素-血管紧张素系统(RAS)的激活通过氧化应激导致肾脏损伤。肾素是血管紧张素(ANG II)生成的限速步骤。最近的研究表明,肾素抑制可改善蛋白尿,与血管紧张素 1 型受体(AT1R)阻断剂(ARB)相当。因此,我们研究了肾素抑制剂与 ARB 治疗对转基因 Ren2 大鼠肾脏氧化应激及相关肾小球结构和功能变化的相对影响,该大鼠表现为高血压、白蛋白尿和组织 RAS 活性增加。年轻的 Ren2 和年龄匹配的 Sprague-Dawley(SD)对照(6-9 周龄)用肾素抑制剂(阿利克仑)、ARB(厄贝沙坦)或载体治疗 21 天。Ren2 大鼠的收缩压(SBP)、白蛋白尿和肾脏 3-硝基酪氨酸含量增加,以及足细胞突起融合和足细胞特异性蛋白nephrin 减少。与 SD 对照组相比,结构和功能改变伴随着肾皮质 ANG II、AT1R 以及 NADPH 氧化酶亚基(Nox2)表达增加。阿利克仑和厄贝沙坦治疗均可使这些异常减轻到相似程度。尽管厄贝沙坦的剂量导致 SBP 降低幅度大于阿利克仑(P < 0.05),但两种治疗方法对蛋白尿、nephrin 和氧化应激的影响相似。我们的结果强调了降压相关的足细胞完整性和白蛋白尿的重要性,以及 ARB 和肾素抑制治疗中 RAS 介导的氧化应激之间的相似性。

相似文献

1
Comparative effect of direct renin inhibition and AT1R blockade on glomerular filtration barrier injury in the transgenic Ren2 rat.直接肾素抑制与 AT1R 阻断对转基因 Ren2 大鼠肾小球滤过屏障损伤的比较作用。
Am J Physiol Renal Physiol. 2010 Mar;298(3):F655-61. doi: 10.1152/ajprenal.00373.2009. Epub 2009 Dec 9.
2
Effect of renin inhibition and AT1R blockade on myocardial remodeling in the transgenic Ren2 rat.肾素抑制和血管紧张素Ⅱ1型受体阻断对转基因Ren2大鼠心肌重塑的影响。
Am J Physiol Endocrinol Metab. 2008 Jul;295(1):E103-9. doi: 10.1152/ajpendo.00752.2007. Epub 2008 May 6.
3
Combination of direct renin inhibition with angiotensin type 1 receptor blockade improves aldosterone but does not improve kidney injury in the transgenic Ren2 rat.直接肾素抑制与1型血管紧张素受体阻断联合应用可改善醛固酮水平,但不能改善转基因Ren2大鼠的肾损伤。
Regul Pept. 2012 Jun 10;176(1-3):36-44. doi: 10.1016/j.regpep.2012.03.002. Epub 2012 Mar 29.
4
Oxidative stress and glomerular filtration barrier injury: role of the renin-angiotensin system in the Ren2 transgenic rat.氧化应激与肾小球滤过屏障损伤:肾素-血管紧张素系统在Ren2转基因大鼠中的作用
Am J Physiol Renal Physiol. 2006 Dec;291(6):F1308-14. doi: 10.1152/ajprenal.00167.2006. Epub 2006 Jun 20.
5
Mineralocorticoid receptor antagonism attenuates glomerular filtration barrier remodeling in the transgenic Ren2 rat.盐皮质激素受体拮抗作用可减轻转基因Ren2大鼠的肾小球滤过屏障重塑。
Am J Physiol Renal Physiol. 2009 May;296(5):F1013-22. doi: 10.1152/ajprenal.90646.2008. Epub 2009 Mar 4.
6
Renin inhibition and AT(1)R blockade improve metabolic signaling, oxidant stress and myocardial tissue remodeling.肾素抑制和 AT(1)R 阻断可改善代谢信号、氧化应激和心肌组织重构。
Metabolism. 2013 Jun;62(6):861-72. doi: 10.1016/j.metabol.2012.12.012. Epub 2013 Jan 24.
7
Despite similar reduction of blood pressure and renal ANG II and ET-1 levels aliskiren but not losartan normalizes albuminuria in hypertensive Ren-2 rats.尽管阿利克仑和氯沙坦均可降低血压和肾血管紧张素 II(ANG II)及内皮素-1(ET-1)水平,但只有阿利克仑可使高血压 Ren-2 大鼠的蛋白尿恢复正常。
Physiol Res. 2010;59(3):339-345. doi: 10.33549/physiolres.931900.
8
Direct renin inhibition with aliskiren normalizes blood pressure in Cyp1a1-Ren2 transgenic rats with inducible angiotensin ii-dependent malignant hypertension.阿利吉仑直接抑制肾素可使 CYP1A1-Ren2 转基因大鼠的血压正常化,该大鼠具有诱导性血管紧张素 II 依赖性恶性高血压。
Am J Med Sci. 2011 May;341(5):383-7. doi: 10.1097/MAJ.0b013e31820fa8da.
9
Renin-angiotensin blockade resets podocyte epigenome through Kruppel-like Factor 4 and attenuates proteinuria.肾素-血管紧张素阻断通过 Kruppel 样因子 4 重置足细胞表观基因组,从而减轻蛋白尿。
Kidney Int. 2015 Oct;88(4):745-53. doi: 10.1038/ki.2015.178. Epub 2015 Jun 24.
10
Attenuation of NADPH oxidase activation and glomerular filtration barrier remodeling with statin treatment.他汀类药物治疗可减轻NADPH氧化酶激活及肾小球滤过屏障重塑。
Hypertension. 2008 Feb;51(2):474-80. doi: 10.1161/HYPERTENSIONAHA.107.102467. Epub 2008 Jan 2.

引用本文的文献

1
Decades-old renin inhibitors are still struggling to find a niche in antihypertensive therapy. A fleeting look at the old and the promising new molecules.几十年来,肾素抑制剂在抗高血压治疗中仍在努力寻找一席之地。短暂地看一下旧的和有前途的新分子。
Bioorg Med Chem. 2020 May 15;28(10):115466. doi: 10.1016/j.bmc.2020.115466. Epub 2020 Mar 28.
2
Treatment of nephrotic syndrome: going beyond immunosuppressive therapy.肾病综合征的治疗:超越免疫抑制疗法。
Pediatr Nephrol. 2020 Apr;35(4):569-579. doi: 10.1007/s00467-019-04225-7. Epub 2019 Mar 23.
3
The effect of aliskiren on the renal dysfunction following unilateral ureteral obstruction in the rat.阿利吉仑对大鼠单侧输尿管梗阻后肾功能障碍的影响。
Int J Physiol Pathophysiol Pharmacol. 2016 Aug 5;8(2):70-7. eCollection 2016.
4
The podocyte as a direct target for treatment of glomerular disease?足细胞作为肾小球疾病治疗的直接靶点?
Am J Physiol Renal Physiol. 2016 Jul 1;311(1):F46-51. doi: 10.1152/ajprenal.00184.2016. Epub 2016 Apr 20.
5
Can Aliskiren be Considered as a New Novel Drug for Hypertension?阿利吉仑可被视为一种治疗高血压的新型药物吗?
Cureus. 2015 Nov 4;7(11):e375. doi: 10.7759/cureus.375.
6
Olmesartan attenuates tacrolimus-induced biochemical and ultrastructural changes in rat kidney tissue.奥美沙坦减轻他克莫司诱导的大鼠肾组织生化和超微结构变化。
Biomed Res Int. 2014;2014:607246. doi: 10.1155/2014/607246. Epub 2014 May 28.
7
Role of NADPH oxidase-mediated reactive oxygen species in podocyte injury.NADPH 氧化酶介导线粒体活性氧在足细胞损伤中的作用。
Biomed Res Int. 2013;2013:839761. doi: 10.1155/2013/839761. Epub 2013 Nov 11.
8
Central angiotensin-(1-7) improves vagal function independent of blood pressure in hypertensive (mRen2)27 rats.中枢血管紧张素-(1-7)可改善高血压(mRen2)27 大鼠的迷走神经功能,而不依赖于血压。
Hypertension. 2012 Nov;60(5):1257-65. doi: 10.1161/HYPERTENSIONAHA.112.196782. Epub 2012 Oct 8.
9
Mineralocorticoid Receptor Blocker Protects against Podocyte-Dependent Glomerulosclerosis.盐皮质激素受体阻滞剂可预防足细胞依赖性肾小球硬化。
Nephron Extra. 2012 Jan;2(1):17-26. doi: 10.1159/000334961. Epub 2012 Jan 31.
10
Combination of direct renin inhibition with angiotensin type 1 receptor blockade improves aldosterone but does not improve kidney injury in the transgenic Ren2 rat.直接肾素抑制与1型血管紧张素受体阻断联合应用可改善醛固酮水平,但不能改善转基因Ren2大鼠的肾损伤。
Regul Pept. 2012 Jun 10;176(1-3):36-44. doi: 10.1016/j.regpep.2012.03.002. Epub 2012 Mar 29.

本文引用的文献

1
Nebivolol reduces proteinuria and renal NADPH oxidase-generated reactive oxygen species in the transgenic Ren2 rat.奈必洛尔可降低转基因Ren2大鼠的蛋白尿水平及肾脏中烟酰胺腺嘌呤二核苷酸磷酸氧化酶产生的活性氧。
Am J Nephrol. 2009;30(4):354-60. doi: 10.1159/000229305. Epub 2009 Jul 17.
2
Aliskiren: a novel renoprotective agent or simply an alternative to ACE inhibitors?阿利吉仑:一种新型肾脏保护剂还是仅仅是血管紧张素转换酶抑制剂的替代品?
Kidney Int. 2009 Jul;76(1):23-31. doi: 10.1038/ki.2009.105. Epub 2009 Apr 15.
3
Direct renin inhibition improves systemic insulin resistance and skeletal muscle glucose transport in a transgenic rodent model of tissue renin overexpression.在组织肾素过表达的转基因啮齿动物模型中,直接抑制肾素可改善全身胰岛素抵抗和骨骼肌葡萄糖转运。
Endocrinology. 2009 Jun;150(6):2561-8. doi: 10.1210/en.2008-1391. Epub 2009 Feb 26.
4
Low aerobic capacity and high-fat diet contribute to oxidative stress and IRS-1 degradation in the kidney.低有氧能力和高脂饮食会导致肾脏中的氧化应激和胰岛素受体底物-1(IRS-1)降解。
Am J Nephrol. 2009;30(2):112-9. doi: 10.1159/000204362. Epub 2009 Feb 20.
5
Redox control of renal function and hypertension.肾功能与高血压的氧化还原调控
Antioxid Redox Signal. 2008 Dec;10(12):2047-89. doi: 10.1089/ars.2008.2034.
6
Renin inhibition attenuates insulin resistance, oxidative stress, and pancreatic remodeling in the transgenic Ren2 rat.肾素抑制可减轻转基因Ren2大鼠的胰岛素抵抗、氧化应激和胰腺重塑。
Endocrinology. 2008 Nov;149(11):5643-53. doi: 10.1210/en.2008-0070. Epub 2008 Jul 24.
7
Renin inhibitor aliskiren improves impaired nitric oxide bioavailability and protects against atherosclerotic changes.肾素抑制剂阿利吉仑可改善一氧化氮生物利用度受损的情况,并预防动脉粥样硬化性改变。
Hypertension. 2008 Sep;52(3):563-72. doi: 10.1161/HYPERTENSIONAHA.108.111120. Epub 2008 Jul 21.
8
Renal and hormonal responses to direct renin inhibition with aliskiren in healthy humans.阿利吉仑对健康人体直接抑制肾素的肾脏和激素反应。
Circulation. 2008 Jun 24;117(25):3199-205. doi: 10.1161/CIRCULATIONAHA.108.767202. Epub 2008 Jun 16.
9
Aliskiren combined with losartan in type 2 diabetes and nephropathy.阿利吉仑与氯沙坦联合用于2型糖尿病和肾病
N Engl J Med. 2008 Jun 5;358(23):2433-46. doi: 10.1056/NEJMoa0708379.
10
Effects of aliskiren on blood pressure, albuminuria, and (pro)renin receptor expression in diabetic TG(mRen-2)27 rats.阿利吉仑对糖尿病TG(mRen - 2)27大鼠血压、蛋白尿及(前)肾素受体表达的影响
Hypertension. 2008 Jul;52(1):130-6. doi: 10.1161/HYPERTENSIONAHA.107.108845. Epub 2008 May 19.